PositiveSPX4,283.850.24%Positive
PositiveIXIC13,276.420.36%Positive
PositiveDJI33,573.280.03%Positive
PositiveSTOXX461.680.38%Positive
PositiveFTSE7,628.100.37%Positive
PositiveN22532,506.78

Neurocrine Biosciences Inc

NBIX.O

Official Data Partner

Latest Trade: trading higher95.41USD
Change; 1.55; 1.65%Positive

As of Jun 6 2023. Values delayed up to 15 minutes

Today's Range: 93.12 - 95.75
52 Week Range: 88.38 - 129.29

Previous Close: 93.86
Open: 93.86
Volume: 637,948.00
3 Month Average Trading Volume: 14.81
Shares Out (Mil): 97.57
Market Cap: 9,158.37
Forward P/E: 43.92
Dividend Yield: 0.00

Key Statistics

1.96 mean rating - 28 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): 153.85
Price To Sales (TTM): 5.73
Price To Book (Quarterly): 5.43
Price To Cash Flow (Per Share TTM): 112.65
Total Debt/Total Equity (Quarterly): 10.06
Long Term Debt/Equity (Quarterly): 10.06
Return On Investment (TTM): 3.30
Return On Equity (TTM): 2.84

2021 (millions USD)

About Neurocrine Biosciences Inc (NBIX.O)

Company Information

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

Address

12780 El Camino Real
SAN DIEGO, CA
92130-2042
United States

Contact Information

+1 (858) 6177600

https://www.neurocrine.com/

Industry

Biotechnology & Drugs

Executive Leadership

William H. Rastetter: Non-Executive Independent Chairman of the Board
Kevin C. Gorman: Chief Executive Officer, Director
Matthew C. Abernethy: Chief Financial Officer
Julie S. Cooke: Chief Human Resource Officer
Jude Onyia: Chief Scientific Officer
Eric S. Benevich: Chief Commercial Officer
David Warren Boyer: Chief Corporate Affairs Officer
Ingrid Delaet: Chief Regulatory Officer
Kyle W. Gano: Chief Business Development and Strategy Officer
Eiry Wyn Roberts: Chief Medical Officer
Darin M. Lippoldt: Chief Legal Officer, Corporate Secretary
Gary A. Lyons: Independent Director
Johanna Mercier: Independent Director
George J. Morrow: Independent Director
Leslie V. Norwalk: Independent Director
Richard F. Pops: Independent Director
Shalini Sharp: Independent Director
Stephen A. Sherwin: Independent Director

Latest News

MarketscategoryU.S. RESEARCH ROUNDUP Akamai Technologies, Gitlab, RPM International
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Akamai Technologies, Gitlab and RPM International, on Thursday.
January 6, 2022
MarketscategoryU.S. RESEARCH ROUNDUP Datadog, Home Depot, Walmart
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, Home Depot and Walmart, on Friday.
November 19, 2021